Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj
NCT02532569
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
94
Enrollment
INDUSTRY
Sponsor class
Conditions
Japanese Encephalitis
Interventions
BIOLOGICAL:
Japanese encephalitis vaccine
Sponsor
Boryung Pharmaceutical Co., Ltd